Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Corpuscle01:20

Renal Corpuscle

1.8K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
1.8K
Renal Drug Excretion: Glomerular Filtration01:02

Renal Drug Excretion: Glomerular Filtration

224
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
224
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
Drug Elimination by Renal Route: Glomerular Filtration01:17

Drug Elimination by Renal Route: Glomerular Filtration

5.6K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production takes place. A nephron has two main components: a renal corpuscle and a renal tubule. Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent...
5.6K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

144
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
144
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the Standardized Outcomes in Nephrology-Life Participation (SONG-LP) Instrument in People with CKD.

Kidney360·2026
Same author

2026 ISPD Position Statement on tracking and reporting loss from PD therapy.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same author

Pilot randomised controlled trial evaluating feasibility, safety and adherence to psyllium husk in peritoneal dialysis: The FIBRE-PD trial.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same author

Procedure-related PD-peritonitis following gastroscopy and colonoscopy: A 15-year binational data-linkage study from Australia and New Zealand.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same author

Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis.

Clinical and translational medicine·2026
Same author

Artificial Intelligence-Electrocardiography to Predict Incident Atrial Fibrillation and Clinical Outcomes in Kidney Transplant Recipients.

Kidney360·2026

Related Experiment Video

Updated: Jun 18, 2025

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells
10:23

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells

Published on: November 4, 2022

3.0K

Drug repurposing for glomerular diseases: an underutilized resource.

Monica Suet Ying Ng1,2,3,4, Gursimran Kaur5,6,7, Ross S Francis8,9

  • 1Kidney Health Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. monica.ng@health.qld.gov.au.

Nature Reviews. Nephrology
|July 31, 2024
PubMed
Summary

Drug repurposing offers new steroid-free treatments for glomerular diseases, including options for children and underserved populations. Data-driven and experimental methods identify potential candidates, expanding therapeutic strategies.

More Related Videos

An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney
10:14

An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney

Published on: November 1, 2018

13.6K
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.6K

Related Experiment Videos

Last Updated: Jun 18, 2025

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells
10:23

Isogenic Kidney Glomerulus Chip Engineered from Human Induced Pluripotent Stem Cells

Published on: November 4, 2022

3.0K
An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney
10:14

An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney

Published on: November 1, 2018

13.6K
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.6K

Area of Science:

  • Nephrology
  • Pharmacology
  • Drug Discovery

Background:

  • Glomerular diseases present challenges with current treatments, necessitating novel therapeutic approaches.
  • Steroid-dependent regimens and limited options for resistant cases highlight the need for alternative strategies.
  • Understudied populations and resource-limited settings require accessible and effective treatment solutions.

Purpose of the Study:

  • To explore the potential of drug repurposing for treating glomerular diseases.
  • To identify existing drugs that can be repurposed for glomerular disease management.
  • To outline strategies for expanding drug repurposing efforts in this field.

Main Methods:

  • Data-driven identification using disease pathobiology, drug features, and clinical outcomes.
  • Experimental identification through high-throughput drug screening.
  • Analysis of drug databases, clinical trial registries, and PubMed for potential candidates.

Main Results:

  • At least 96 approved drugs targeting 49 immunosuppressive pathways are potential candidates for glomerular disease repurposing.
  • Evidence supports 191 immune drug target-glomerular disease pairs for repurposing.
  • Non-immunological strategies target haemodynamic overload, podocyte injury, and kidney fibrosis.

Conclusions:

  • Drug repurposing offers steroid-free, personalized, and multi-target treatment opportunities for glomerular diseases.
  • Expanding drug repurposing requires enriched databases, accessible clinical data, biomarker discovery, and reduced regulatory hurdles.
  • This approach can enhance treatment options for diverse patient groups and settings.